摘要
目的探讨黄芪注射液辅助雷替曲塞联合奥沙利铂治疗晚期结直肠癌的近期疗效和对免疫功能的影响。方法选择晚期结直肠癌患者93例,随机分为对照组(n=46)和观察组(n=47)。对照组给予雷替曲塞(3 mg·m^(-2))和奥沙利铂(130 mg·m^(-2)),均静脉滴注。观察组除对照组治疗外,辅用黄芪注射液60 mL静脉滴注,qd。两组均为三周一个疗程,总疗程数≤6个(18周)。两组于治疗前和治疗后三个疗程评价其疗效,观察CD^(3+)、CD^(4+)细胞、CD^(3+)/CD^(8+)变化,记录其不良反应。结果对照组和观察组治疗有效率、疾病控制率比较无显著差异(P>0.05)。观察组中位无疾病进展时间为11.6个月,显著高于对照组的9.4个月(95%CI:1.035~2.426,P=0.029)。治疗三个疗程后观察组CD^(4+)/CD^(8+)为(1.30±0.17),明显高于对照组的(1.15±0.14)(P<0.05)。观察组恶心、呕吐和神经毒性发生率分别为57%、36%和23%,显著低于对照组的85%、61%和52%(P<0.05)。结论黄芪注射液辅助治疗能延长雷替曲塞联合奥沙利铂治疗晚期结直肠癌的中位无疾病进展时间,提高机体免疫力。
AIM To study the short-term therapeutical efficacy combined with oxaliplatin in treatment of advanced colorectal cancer of Huangqi injection plus raltitrexed and its effects on immune function. METHODS Ninty-three patients with advanced colorectal cancer were randomly divided into control group （n = 46） and observation group （n = 47）. The patients in the control group were given raltitrexed 3 mg .m-2 combined with oxaliplatin 130 mg .m-2 through intravenous injection. In addition to giving rahitrexed and oxaliplatin, the patients in the control group also received Huangqi injection 60 mL through intravenous infusion, qd. Three weeks were defined as one circle, and the total circles ≤6 （18 weeks）. The therapeutical efficacy, adverse reactions, the changes of CD3＋ cell, CD4＋ cell and CD4＋/CD8＋, and immune function after 3 circles in two groups were compared. RESULTS There were no significant statistical differences in treatment efficiency and disease control rate between the observation and control group （P 〉 0.05）. The median without progressed for the observation group was 11.6 months, significantly higher than the control group which was 9.4 months （95% CI： 1.035 - 2.426, P = 0.029）. After three courses, the CD4＋/CD8＋ in the observation group （ 1.30 ± 0.17） was significantly higher than that of the control group （ 1.15 ± 0.14） （P 〈 0.05）. The rate of nausea, vomit and neurotoxicity in the observation group were 57%, 36% and 23% respectively, which were significantly lower than those in the control group （P 〈 0.05）, of which were 85%, 61% and 52% respectively. CONCLUSION Huangqi injection plus rahitrexed combined with oxaliplatin could extend the median progression-free survival and the immune function in the treatment of advanced colorectal cancer patients.
出处
《中国新药与临床杂志》
CAS
CSCD
北大核心
2014年第3期218-221,共4页
Chinese Journal of New Drugs and Clinical Remedies
关键词
黄芪注射液
雷替曲塞
奥沙利铂
结直肠肿瘤
近期疗效
免疫功能
Huangqi injeetion
raltitrexed
oxaliplatin
colorectal neoplasms
short-term effeet
immune function
